Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1998-06-10
2001-06-19
Yucel, Remy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S002600, C424S143100, C435S320100, C435S360000, C435S375000, C435S456000, C530S350000, C530S388220, C536S023100, C536S023500
Reexamination Certificate
active
06248723
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method to protect a mammal from a disease involving inflammation, in particular, a respiratory disease involving inflammation.
BACKGROUND OF THE INVENTION
Diseases involving inflammation are characterized by the influx of certain cell types and mediators, the presence of which can lead to tissue damage and sometimes death. Diseases involving inflammation are particularly harmful when they afflict the respiratory system, resulting in obstructed breathing, hypoxemia, hypercapnia and lung tissue damage. Obstructive diseases of the airways are characterized by airflow limitation (i.e., airflow obstruction or narrowing) due to constriction of airway smooth muscle, edema and hypersecretion of mucous leading to increased work in breathing, dyspnea, hypoxemia and hypercapnia. While the mechanical properties of the lungs during obstructed breathing are shared between different types of obstructive airway disease, the pathophysiology can differ.
A variety of inflammatory agents can provoke airflow limitation including allergens, cold air, exercise, infections and air pollution. In particular, allergens and other agents in allergic or sensitized mammals (i.e., antigens and haptens) cause the release of inflammatory mediators that recruit cells involved in inflammation. Such cells include lymphocytes, eosinophils, mast cells, basophils, neutrophils, macrophages, monocytes, fibroblasts and platelets. Inflammation results in airway hyperresponsiveness. A variety of studies have linked the degree, severity and timing of the inflammatory process with the degree of airway hyperresponsiveness. Thus, a common consequence of inflammation is airflow limitation and/or airway hyperresponsiveness.
Asthma is a significant disease of the lung which effects nearly 12 million Americans. Asthma is typically characterized by periodic airflow limitation and/or hyperresponsiveness to various stimuli which results in excessive airways narrowing. Other characteristics can include inflammation of airways, eosinophilia and airway fibrosis.
Airway fibrosis due to the deposition of collagen or provisional matrix beneath the basement membrane is a consistent finding in asthma patients, even in the airways of patients with mild asthma. This deposition of collagen is not altered by steroid treatment. Clinical studies have shown a positive correlation between airway fibrosis and airway dysfunction (e.g., airflow limitation or airways hyperresponsiveness). The inflammatory mechanisms which result in this collagen deposition are unknown and more importantly, the functional significance of airway fibrosis is not understood. There is a need to determine the mechanisms which link inflammation, airways remodeling and pathophysiology in asthma since such mechanisms are likely to have a bearing on disease severity and the efficaciousness of therapeutics, as well as their role in other inflammatory diseases.
Asthma prevalence (i.e., both incidence and duration) is increasing. The current prevalence approaches 10% of the population and has increased 25% in the last 20 years. Of more concern, however, is the rise in the death rate. When coupled with increases in emergency room visits and hospitalizations, recent data suggests that asthma severity is rising. While most cases of asthma are easily controlled, for those with more severe disease, the costs, the side effects and all too often, the ineffectiveness of the treatment, present serious problems. Fibroproliferative responses to chronic antigen exposure may explain both asthma severity and poor responses to therapy, especially if treatment is delayed. The majority of patients with asthma have very mild symptoms which are easily treated, but a significant number of asthmatics have more severe symptoms. Moreover, chronic asthma is associated with the development of progressive and irreversible airflow limitation due to some unknown mechanism.
Currently, therapy for treatment of inflammatory diseases such as moderate to severe asthma predominantly involves the use of glucocorticosteroids. Other anti-inflammatory agents that are used to treat inflammatory diseases include cromolyn and nedocromil. Symptomatic treatment with beta-agonists, anticholinergic agents and methyl xanthines are clinically beneficial for the relief of discomfort but fail to stop the underlying inflammatory processes that cause the disease. The frequently used systemic glucocorticosteroids have numerous side effects, including, but not limited to, weight gain, diabetes, hypertension, osteoporosis, cataracts, atherosclerosis, increased susceptibility to infection, increased lipids and cholesterol, and easy bruising. Aerosolized glucocorticosteroids have fewer side effects but can be less potent and have significant side effects, such as thrush.
Other anti-inflammatory agents, such as cromolyn and nedocromil are much less potent and have fewer side effects than glucocorticosteroids. Anti-inflammatory agents that are primarily used as immunosuppressive agents and anti-cancer agents (i.e., cytoxan, methotrexate and Immuran) have also been used to treat inflammation with mixed results. These agents, however, have serious side effect potential, including, but not limited to, increased susceptibility to infection, liver toxicity, drug-induced lung disease, and bone marrow suppression. Thus, such drugs have found limited clinical use for the treatment of most airway hyperresponsiveness lung diseases.
The use of anti-inflammatory and symptomatic relief reagents is a serious problem because of their side effects or their failure to attack the underlying cause of an inflammatory response. There is a continuing requirement for less harmful and more effective reagents for treating inflammation. Thus, there remains a need for processes using reagents with lower side effect profiles and less toxicity than current anti-inflammatory therapies.
SUMMARY OF THE INVENTION
The present invention provides for a method and a formulation for protecting a mammal from diseases involving inflammation. The present invention is particularly advantageous in that it targets a specific family of molecules which are shown herein to play a complex and prominent role in both inflammation and airway fibrosis, thereby reducing the side effects and toxicity profiles frequently associated with non-specific anti-inflammatory therapies.
One embodiment of the present invention includes a method to protect a mammal from a respiratory disease involving an inflammatory response, the method comprising administering to the mammal a TGF&bgr;-regulating agent selected from the group of a pan-specific TGF&bgr;-inhibiting agent, a TGF&bgr;1-stimulating agent, TGF&bgr;1, a TGF&bgr;2-inhibiting agent, a TGF&bgr;3-inhibiting agent and combinations thereof. The method of the present invention is particularly effective in protecting mammals from respiratory diseases by reducing airway hyperresponsiveness, decreasing methacholine responsiveness, decreasing lung inflammation and/or decreasing airways fibroproliferation. Preferably, the method of the present invention reduces the airflow limitation of a mammal such that the FEV
1
/FVC value of the mammal is improved by at least about 5% (or at least 100 cc or PGFRg 10 L/min). Administration of the TGF&bgr;-regulating agent can result in an improvement in a mammal's PC
20methacholine
FEV
1
value such that the PC
20methacholine
FEV
1
value obtained before administration of the TGF&bgr;-regulating agent when the mammal is provoked with a first concentration of methacholine is the same as the PC
20methacholine
FEV
1
value obtained after administration of the TGF&bgr;-regulating agent when the mammal is provoked with double the amount of the first concentration of methacholine.
Diseases from which a mammal can be protected by the method of the present invention include, but are not limited to, chronic obstructive pulmonary diseases of the airways, as well as diseases including asthma, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonia, eosi
National Jewish Medical and Research Center
Sheridan & Ross P.C.
Shibuya Mark L.
Yucel Remy
LandOfFree
Method for treatment of inflammatory disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of inflammatory disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of inflammatory disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2517208